Antibody drug found cost-effective against allergic asthma
NEW YORK A review of seven studies has found the antibody drug Xolair to be cost-effective in treating allergic asthma, according to a report published in the journal Allergy.
The report, by University of Washington researcher Sean Sullivan and Dr. F. Turk of Novartis Pharma showed that Xolair, Novartis’ brand name for omalizumab, showed the drug was cost-effective in treating allergic asthma for which common asthma medications were inadequate.
The studies also found some evidence that Xolair may not be as cost-effective in treating other forms of asthma.
Novartis and Genentech market Xolair in the U.S. Genentech reported U.S. sales of $472 million for the drug in 2007, according to Novartis financial data.
FDA, EMEA partner on inspections program
WASHINGTON The Food and Drug Administration and the European Medicines Agency have joined together to pilot a good manufacturing practice inspections program.
Under the bilateral agreement, the program will apply to facilities in both the U.S. and the European Union. Also, joint inspections of active pharmaceutical ingredient facilities in countries outside the U.S. and the EU will be part of the program.
The agencies will pilot a GMP information exchange covering inspection schedules and results. Information on facilities that have been inspected would be shared so the agencies could get greater inspection coverage and better identify API production sites in countries outside the U.S. and the EU.
“The collaboration on inspections should result in more effective use of resources and a higher safety level of product from third countries,” the European Commission, which lists new GMP initiatives the two agencies undertake, said.
Study shows Mass. plan drops uninsurance rate, decreases expenses
CHICAGO According to a study performed by the Urban Institute, the uninsurance rate for Massachusetts adults has dropped by more than half and residents were paying less in out-of-pocket health expenses, as reported by the Associated Press.
Researchers from the institute interviewed 3,000 Massachusetts residents in the fall of 2006, just before the law took effect, and conducted a second round of interviews a year later. The uninsurance rate among working age adults dropped from 13 to 7 percent. The biggest drop was among poorer residents.
The finding reflects the fact that nearly 350,000 residents have been added to the ranks of the insured in Massachusetts under the law, which created a subsidized health care program for those earning less than three times the federal poverty level.
The share of adults reporting out-of-pocket expenses of more than $500 dropped by four percent. The percent of low-income adults reporting out-of-pocket expenses of more than $3,000 fell eight percent.
In another positive finding, low-income adults were more likely to have a place to go when they were sick and were more likely to visit a doctor for preventative care.
One fear—that employers would begin dropping health coverage as the new law took effect—hasn’t materialized, according to the report.